ClinicalTrials.gg
CompletedNCT03013504TROIKAUpdated Nov 6, 2024

A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients

A Phase 3 interventional study of HD201 and Herceptin in HER2 Positive Breast Cancer, sponsored by Prestige Biopharma Limited. Completed at 15 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by Prestige Biopharma Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
503
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
35th of 366
503 · median 61
Started
2018
with 7 others
Phase 3
60 of 374
3 open now
Registered
251st of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 35th largest by enrollment of the 366 interventional ones that give a count, is one of 8 that started in 2018, is one of 60 in phase 3, and was the 251st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.

Read the detailed description

This is a randomised, double-blind, parallel group, equivalence, multicentre Phase III study. 500 patients with HER2+ early breast cancer (EBC) will be randomised (1:1) to receive either HD201 in combination with chemotherapy (n=250) or Herceptin® in combination with chemotherapy (n=250).

HD201 or Herceptin® will be administered every 3 weeks for 8 cycles(24 weeks). After administration of the final neoadjuvant study drug dose, surgery will be done within 3-8 weeks followed by an adjuvant treatment period for 10 cycles.

Patients completing the 18 cycles of treatment and those discontinuing the study will attend an End of Treatment (EOT) visit 4 weeks (+/- 2 days), after last administration of study medication, followed by a follow-up period of 2 years.

Patients will attend study visits every 3 weeks. At each visit, patients will undergo a complete physical examination, vital signs, weight, performance status, clinical laboratory tests and adverse events (AEs), concomitant medication will be recorded. After the EOT visit patients will be followed every 6 months for an additional 24 months or until death, whichever occurs first, to collect data on cardiac safety and disease status.

Cardiac safety will be assessed by echocardiography or multigated acquisition (MUGA) scan to evaluate the left ventricular ejection fraction (LVEF) (at screening, before cycle 5, before surgery, before cycles 12 and 16, EOT visit, and at 6 and 12 months after the completion of trastuzumab (more frequent if necessary)) and by means of a 12-lead ECG (at screening, before cycle 5, before surgery, before cycles 12 and 16, EOT visit, and at 6 and 12 months after the completion of trastuzumab).

The primary efficacy endpoint, total pathological complete response (tpCR) will be assessed at the time of surgery after neoadjuvant treatment completion after 24 weeks. tpCR will be assessed both by local and by central reading.

Sampling for pharmacokinetics (PK) analysis (determination of Ctrough values) will be performed in all patients before cycle 5 and cycle 8.

An Independent Data Monitoring Committee will be implemented that reviews accumulating data of the clinical trial with respect to any potential safety issues, study progress and critical efficacy endpoints. The members will be selected on the basis of relevant experience and understanding of clinical research and the issues specific to the therapeutic area, as well as previous data monitoring committee experience.

03

Conditions studied

  • HER2 Positive Breast Cancer

Browse trials for

Keywords

  • randomized
  • double-blind
  • parallel group
  • equivalence
  • multicentre
  • phase III
  • efficacy
  • safety
  • pharmacokinetics
  • HD201
  • docetaxel
  • Herceptin
  • HER2 positive
  • breast cancer
  • early breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give written .
  2. Females ≥ 18 years of Age
  3. (ECOG) performance Status (PS) \< 2.
  4. Known Hormone receptor (oestrogen receptor and progesterone receptor) status.
  5. overexpressed as assessed by

    1. Immunohistochemistry (IHC) or
    2. Fluorescent in situ hybridisation (FISH); FISH positive is defined as FISH amplification Ratio ≥ 2.0 / number of HER2 gene copies per cell >2
    3. Chromogenetic in stu hybridisation (CISH) positive
    4. Patients with IHC score 3+ or positive FISH/CISH test
    5. Patients with an IHC score 2+ must also have a positive FISH/CISH test
  6. ≥ 50% or within the normal Level of the Institution, as assessed by echocardiography or MUGA scan.
  7. > 12 weeks.
  8. Adequate bone marrow function as evidenced by the following:

    1. Absolute neutrophils count ≥ 1,500/μL
    2. ≥ 9 g/dL
    3. count ≥ 100,000/μL Up to 5% Deviation is acceptable.
  9. Adequate hepatic and renal function as evidenced by the following:

    1. ≥ 60mL/min
    2. total ≤ 1.5x (ULN)
    3. (SGOT) and ALT (SGPT) ≤ 2.5 x ULN Up to 10% deviation is acceptable.
  10. Ability to comply with the study protocol.
  11. Female patients of must have a negative Serum pregnancy test within 7 days prior to first dose of study treatment and agree to use effective (intrauterine device, diaphragm, diaphragm with spermicide or a reliable barrier method, eg condom with spermicide) throughout the study period and 7 months after discontinuation of study drug.
  12. Non-, unilateral, newly diagnosed, operable early breast cancer (EBC) of clinical stage II and III including inflammatory breast cancer. confirmed primary invasive carcinoma of the breast.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following criteria must not be enrolled in the study:

  1. (stage IV) with exception of supraclavicular nodes.
  2. Bilateral breast cancer
  3. Multicentric breast cancer
  4. History of any prior invasive breast carcinoma, except for subjects with a past history of ductal carcinoma in situ (DCIS) treated with surgery.
  5. History of malignant neoplasms within 5 years prior to randomisation, except for curatively treated carcinoma in situ of uterine cervix, basal cell carcinoma of the skin or squamous cell carcinoma of the skin (malignant neoplasms occurring more than 5 years prior to randomisation are permitted if curatively treated with surgery only).
  6. Previous history of radiation therapy, anti-neoplastic immunotherapy, chemotherapy or anti-neoplastic biotherapy (including prior directed therapy).
  7. Major surgery within 2 weeks prior to randomisation
  8. Serious cardiac illness that would preclude the use of trastuzumab such as:

    • history of documented congestive heart failure (CHF) (, NYHA, class III or greater heart disease)
    • \< 50% by echocardiography or MUGA scan
    • angina pectoris requiring anti-anginal medication
    • evidence of transmural infarction on (ECG)
    • uncontrolled hypertension (systolic > 180 mmHg and/or diastolic > 100 mmHg)
    • valvular heart disease
    • high-risk uncontrolled arrhythmias.
  9. Serious pulmonary illness enough to cause dyspnoea at rest or requiring supplementary oxygen therapy.
  10. Known history of active virus (HBV) and active virus (HCV) infection.
  11. Known infection by patient declaration.
  12. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
  13. Known to the IMPs, non-IMPs or any of the ingredients or of the IMPs or non-IMPs.
  14. Known hypersensitivity to murine proteins.
  15. Pre-existing peripheral sensory or motor neuropathy ≥ grade 2 (as defined by v4.03).
  16. Lactating or pregnant woman. A pregnancy test is required for all women of including women who had menopause onset within 2 years prior to randomisation. Women of childbearing potential must agree to use methods during the study and for 7 months after the last dose of IMP.
  17. Participation in any clinical study or having taken any therapy during the 1-month period immediately preceding administration of the first dose.
  18. Patients unwilling to follow the study requirements.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
503 participants (actual)

Study arms

  • Experimental
    HD201 in combination with docetaxel

    8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by \>1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first. Neoadjuvant chemotherapy: Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion

    Drug: HD201 · Drug: Docetaxel · Drug: Epirubicin · Drug: Cyclophosphamide

  • Active comparator
    Herceptin® in combination with docetaxel

    8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by \>1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first. Neoadjuvant chemotherapy: Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion

    Drug: Herceptin · Drug: Docetaxel · Drug: Epirubicin · Drug: Cyclophosphamide

Interventions

  • DrugHD201

    Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.

    Also known as: Trastuzumab

  • Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.

    Also known as: Trastuzumab

  • 75mg/m2 via i.v. infusion during cycles 1 to 4.

  • 75 mg/m2 via i.v. infusion during cycles 5-8.

  • 500 mg/m2 via i.v. infusion during cycles 5-8.

06

What researchers measure

Primary outcomes

  1. total pathological complete response rate (tpCR)

    To compare the total pathological complete response rate (tpCR) in patients treated with HD201 plus chemotherapy to that in patients treated with Herceptin® plus chemotherapy.

    Time frame: After 24 weeks (end of cycle 8)

Secondary outcomes

  1. total breast pathological complete response rate (bpCR)

    To compare total breast pathological complete response rate (bpCR) between the two arms at the time of surgery.

    Time frame: After 24 weeks (end of cycle 8)

  2. Overall response rate (ORR)

    ORR defined as proportion of patients whose best overall response is either complete response (CR) or partial response (PR) at the time of surgery.

    Time frame: After 24 weeks (end of cycle 8)

  3. Overall Survival (OS)

    OS defined as the time from Day 1 of therapy until death from any cause

    Time frame: From date of randomisation until death from any cause or two years after End of Treatment, whichever comes first

  4. Event-free Survival (EFS)

    EFS defined as the time from Day 1 of therapy (day of first infusion of medication on study) until progression of disease or death from any cause.

    Time frame: From date of randomisation until death from any cause or two years after End of Treatment, whichever comes first

  5. Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)

    Safety and tolerability will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events and CTC v4.03

    Time frame: From baseline through study completion until 18 months or until death, whichever came first

  6. Cardiac dysfunction

    Cardiac dysfunction will be monitored by 12-Lead ECG and measurement of the LVEF by echocardiography or MUGA scan

    Time frame: Within 28 days before start of treatment, before cycle 5,12 and 16 (1 cycle is 3 weeks), before surgery (after 24 weeks), at end of treatment (4 weeks from last administration of drug medication) and one year after completion of trastuzumab therapy.

  7. Immunogenecity

    Incidence of human trastuzumab antibodies

    Time frame: At baseline (within 28 days before start of treatment), before surgery (after 24 weeks), at end of treatment (4 weeks from last administration of drug medication) and one year after completion of trastuzumab therapy.

  8. Clearance (Pharmacokinetic)

    Sampling will be performed in all patients to compare the PK through values of HD201 and Herceptin.

    Time frame: Before administration of treatment at Cycles 5 and 8 (1 cycle is 3 weeks)

  9. Area under the curve (AUC, Pharmacokinetic)

    Sampling will be performed in all patients to compare the PK through values of HD201 and Herceptin.

    Time frame: Before administration of treatment at Cycles 5 and 8 (1 cycle is 3 weeks)

  10. Plasma half life (Pharmacokinetic)

    Sampling will be performed in all patients to compare the PK through values of HD201 and Herceptin.

    Time frame: Before administration of treatment at Cycles 5 and 8 (1 cycle is 3 weeks)

07

Study locations

15 sites
  • Minsk Clinical Oncological Dispensary
    Minsk, 220013, Belarus
  • Complex Oncology Center
    Plovdiv, 4002, Bulgaria
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • Centre René Huguenin (Institut Curie)
    Saint-Cloud, 92210, France
  • S. Khechinashvili University Hospital
    Tbilisi, 0179, Georgia
  • National Institute of Oncology
    Budapest, 1122, Hungary
  • University of Debrecen
    Debrecen, 4032, Hungary
  • Modena Hospital
    Modena, 41124, Italy
  • Beacon International Specialist Centre
    Kuala Lumpur, 46050, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • Szpital Specjalistyczny Brzeziny
    Brzeziny, 95-060, Poland
  • LLC "Vitamed"
    Moscow, 129515, Russian Federation
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • Maharaj Nakorn Chiang Mai Hospital
    Chiang Mai, 50200, Thailand
  • GI "V. T. Zaycev Institute General and Urgent Surgery of NAMS of Ukraine "
    Kharkiv, 61018, Ukraine
08

References and documents

Publications

  • Pivot X, Georgievich MA, Shamrai V, Dzagnidze G, Soo Hoo HF, Kaewkangsadan V, Petrelli F, Villanueva C, Nikolaevich LO, Hii J, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Bonamy GMC, Deforce F, Cox DG. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):698-705. doi: 10.1001/jamaoncol.2021.8171. PubMed 35238873 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Apr 2019, 14 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 14 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2016
First posted
Jan 6, 2017
StartActual
Feb 19, 2018
Primary completionActual
Apr 19, 2019
CompletionActual
Jan 13, 2022
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03013504
Lead sponsor
Prestige Biopharma Limited
Responsible party
Sponsor
First posted
Jan 6, 2017
Start date
Feb 19, 2018
Primary completion
Apr 19, 2019
Completion
Jan 13, 2022
Last update
Nov 6, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion